ArticleWorld journal of urology2025
Influence of PSA level at salvage radiotherapy on metastasis-free survival following radical prostatectomy.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe optimal time point of salvage radiotherapy (sRT) for biochemical recurrence (BCR) following radical prostatectomy is still under debate. Current European guidelines recommend salvage intensity-modulated and image‐guided radiotherapy for men with two consecutive PSA rises. However, no specific PSA threshold for initiation time is recommended. Nonetheless, lower PSA level may be associated with better cancer-control outcomes.
methodsRelying on the University Cancer Center Frankfurt database, we evaluated differences in metastasis-free survival (MFS) among patients treated with early sRT (< 0.5 ng/ml) vs. sRT at PSA ≥ 0.5ng/ml. Subgroup analyses addressed sRT patients with high-risk features for indication of adjuvant radiation therapy, including Gleason score 8–10 and/or pT3–4 stage and/or pN1.
resultsOf 190 sRT patients, 69% received early sRT at median PSA 0.24ng/ml vs. 0.89ng/ml. MFS was significantly better for early sRT patients, relative to sRT at PSA > 0.5 ng/ml (hazard ratio [HR]: 8.44, p < 0.01). Similarly, sRT patients with high-risk features also had significant better MFS at sRT with PSA < 0.5ng/ml (HR: 12.69, p < 0.01). After additional multivariable adjustment, early sRT at PSA < 0.5ng/ml was independently associated with better MFS outcomes for all patients (HR: 8.2) and high-risk sRT subgroups (HR: 55.6, both p < 0.05). Finally, we validated the initiation of sRT at an even lower cut-off of a PSA level ≤ 0.25ng/ml. However, this did not result in a significantly different outcomes, probably due to sample size limitations.
conclusionOur results validate European guidelines’ recommendation to initiate sRT at low PSA levels < 0.5ng/ml providing better MFS, especially in patients with high-risk features, refusing adjuvant radiation therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.